Search Results - "Nakagawa, Kazuhiko"

Combination therapy with PD-1 or PD-L1 inhibitors for cancer by Hayashi, Hidetoshi, Nakagawa, Kazuhiko

“…Immune checkpoint inhibitors (ICIs)—such as antibodies to programmed cell death–1 (PD-1), to its ligand PD-L1, or to cytotoxic T lymphocyte-associated…”
Get full text

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? by Takeda, Masayuki, Nakagawa, Kazuhiko

“…Activating mutations of the epidermal growth factor receptor gene ( ) are a driving force for some lung adenocarcinomas. Several randomized phase III studies…”
Get full text

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer by Solomon, Benjamin J, Mok, Tony, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Tursi, Jennifer, Blackhall, Fiona

“…The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater…”
Get full text

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer by Takeda, Masayuki, Okamoto, Isamu, Nakagawa, Kazuhiko

“…Highlights • Afatinib, erlotinib, and gefitinib are available for EGFR mutation-positive NSCLC. • Severe rash and diarrhea were more frequent with afatinib…”
Get full text

Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis by Aogi, Kenjiro, Takeuchi, Hideki, Saeki, Toshiaki, Aiba, Keisuke, Tamura, Kazuo, Iino, Keiko, Imamura, Chiyo K., Okita, Kenji, Kagami, Yoshikazu, Tanaka, Ryuhei, Nakagawa, Kazuhiko, Fujii, Hirofumi, Boku, Narikazu, Wada, Makoto, Akechi, Tatsuo, Iihara, Hirotoshi, Ohtani, Shoichiro, Okuyama, Ayako, Ozawa, Keiko, Kim, Yong-Il, Sasaki, Hidenori, Shima, Yasuo, Takeda, Masayuki, Nagasaki, Eijiro, Nishidate, Toshihiko, Higashi, Takahiro, Hirata, Kouichi

“…Patients with cancer should appropriately receive antiemetic therapies against chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an…”
Get full text

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies by Piha‐Paul, Sarina A., Oh, Do‐Youn, Ueno, Makoto, Malka, David, Chung, Hyun Cheol, Nagrial, Adnan, Kelley, Robin K., Ros, Willeke, Italiano, Antoine, Nakagawa, Kazuhiko, Rugo, Hope S., Braud, Filippo, Varga, Andrea Iolanda, Hansen, Aaron, Wang, Hui, Krishnan, Suba, Norwood, Kevin G., Doi, Toshihiko

“…We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE‐158 (NCT02628067; phase 2) and KEYNOTE‐028…”
Get full text

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer by Solomon, Benjamin J, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Tang, Yiyun, Wilner, Keith D, Blackhall, Fiona, Mok, Tony S

“…Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK)…”
Get full text

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) by Okada, Morihito, Kijima, Takashi, Aoe, Keisuke, Kato, Terufumi, Fujimoto, Nobukazu, Nakagawa, Kazuhiko, Takeda, Yuichiro, Hida, Toyoaki, Kanai, Kuninobu, Imamura, Fumio, Oizumi, Satoshi, Takahashi, Toshiaki, Takenoyama, Mitsuhiro, Tanaka, Hiroshi, Hirano, Jun, Namba, Yoshinobu, Ohe, Yuichiro

“…PURPOSEMalignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard…”
Get full text

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset by Ohe, Yuichiro, Imamura, Fumio, Nogami, Naoyuki, Okamoto, Isamu, Kurata, Takayasu, Kato, Terufumi, Sugawara, Shunichi, Ramalingam, Suresh S, Uchida, Hirohiko, Hodge, Rachel, Vowler, Sarah L, Walding, Andrew, Nakagawa, Kazuhiko

“…In the FLAURA trial Japanese subset, osimertinib significantly improved median PFS versus standard-of-care (gefitinib) in patients with previously untreated…”
Get full text

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer by Isomoto, Kohsuke, Haratani, Koji, Hayashi, Hidetoshi, Shimizu, Shigeki, Tomida, Shuta, Niwa, Takashi, Yokoyama, Toshihide, Fukuda, Yasushi, Chiba, Yasutaka, Kato, Ryoji, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Ogura, Takashi, Ishida, Tadashi, Ito, Akihiko, Nakagawa, Kazuhiko

“…The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune microenvironment (TME) in non-small cell lung cancer (NSCLC) is unclear. We…”
Get full text

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity by Yonesaka, Kimio, Haratani, Koji, Takamura, Shiki, Sakai, Hitomi, Kato, Ryoji, Takegawa, Naoki, Takahama, Takayuki, Tanaka, Kaoru, Hayashi, Hidetoshi, Takeda, Masayuki, Kato, Sigeki, Maenishi, Osamu, Sakai, Kazuko, Chiba, Yasutaka, Okabe, Takafumi, Kudo, Keita, Hasegawa, Yoshikazu, Kaneda, Hiroyasu, Yamato, Michiko, Hirotani, Kenji, Miyazawa, Masaaki, Nishio, Kazuto, Nakagawa, Kazuhiko

“…Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non-small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby…”
Get full text

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial by Hida, Toyoaki, MD, Nokihara, Hiroshi, MD, Kondo, Masashi, MD, Kim, Young Hak, MD, Azuma, Koichi, MD, Seto, Takashi, MD, Takiguchi, Yuichi, Prof, Nishio, Makoto, MD, Yoshioka, Hiroshige, MD, Imamura, Fumio, MD, Hotta, Katsuyuki, Prof, Watanabe, Satoshi, MD, Goto, Koichi, MD, Satouchi, Miyako, MD, Kozuki, Toshiyuki, MD, Shukuya, Takehito, MD, Nakagawa, Kazuhiko, Prof, Mitsudomi, Tetsuya, Prof, Yamamoto, Nobuyuki, Prof, Asakawa, Takashi, PhD, Asabe, Ryoichi, MS, Tanaka, Tomohiro, MS, Tamura, Tomohide, Dr

“…Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability…”
Get full text

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer by Reck, Martin, Luft, Alexander, Szczesna, Aleksandra, Havel, Libor, Kim, Sang-We, Akerley, Wallace, Pietanza, Maria Catherine, Wu, Yi-Long, Zielinski, Christoph, Thomas, Michael, Felip, Enriqueta, Gold, Kathryn, Horn, Leora, Aerts, Joachim, Nakagawa, Kazuhiko, Lorigan, Paul, Pieters, Anne, Kong Sanchez, Teresa, Fairchild, Justin, Spigel, David

“…Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and…”
Get full text

Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L by Sakata, Shinya, Otsubo, Kohei, Yoshida, Hisako, Ito, Kentaro, Nakamura, Atsushi, Teraoka, Shunsuke, Matsumoto, Naohisa, Shiraishi, Yoshimasa, Haratani, Koji, Tamiya, Motohiro, Ikeda, Satoshi, Miura, Satoru, Tanizaki, Junko, Omori, Shota, Yoshioka, Hiroshige, Hata, Akito, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko

“…Considering the increasing number of identified driver oncogene alterations, additional genetic tests are required to determine the treatment for advanced…”
Get full text

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study by Seto, Takashi, MD, Kato, Terufumi, MD, Nishio, Makoto, MD, Goto, Koichi, MD, Atagi, Shinji, MD, Hosomi, Yukio, MD, Yamamoto, Noboru, MD, Hida, Toyoaki, MD, Maemondo, Makoto, MD, Nakagawa, Kazuhiko, Prof, Nagase, Seisuke, MD, Okamoto, Isamu, MD, Yamanaka, Takeharu, PhD, Tajima, Kosei, MSc, Harada, Ryosuke, BS, Fukuoka, Masahiro, MD, Yamamoto, Nobuyuki, Prof

“…Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer…”
Get full text

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer by Shaw, Alice T, Kim, Dong-Wan, Nakagawa, Kazuhiko, Seto, Takashi, Crinó, Lucio, Ahn, Myung-Ju, De Pas, Tommaso, Besse, Benjamin, Solomon, Benjamin J, Blackhall, Fiona, Wu, Yi-Long, Thomas, Michael, O'Byrne, Kenneth J, Moro-Sibilot, Denis, Camidge, D. Ross, Mok, Tony, Hirsh, Vera, Riely, Gregory J, Iyer, Shrividya, Tassell, Vanessa, Polli, Anna, Wilner, Keith D, Jänne, Pasi A

“…In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based…”
Get full text

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival by Lee, Chee Khoon, Davies, Lucy, Wu, Yi-Long, Mitsudomi, Tetsuya, Inoue, Akira, Rosell, Rafael, Zhou, Caicun, Nakagawa, Kazuhiko, Thongprasert, Sumitra, Fukuoka, Masahiro, Lord, Sally, Marschner, Ian, Tu, Yu-Kang, Gralla, Richard J, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin

“…We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase…”
Get full text

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification by Takegawa, Naoki, Tsurutani, Junji, Kawakami, Hisato, Yonesaka, Kimio, Kato, Ryoji, Haratani, Koji, Hayashi, Hidetoshi, Takeda, Masayuki, Nonagase, Yoshikane, Maenishi, Osamu, Nakagawa, Kazuhiko

“…Therapies targeted to human epidermal growth factor receptor 2 (HER2) have proven effective against tumors positive for HER2 amplification, but there is an…”
Get full text

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial by Soria, Jean-Charles, Prof, Wu, Yi-Long, Prof, Nakagawa, Kazuhiko, Prof, Kim, Sang-We, Prof, Yang, Jin-Ji, MD, Ahn, Myung-Ju, Prof, Wang, Jie, MD, Yang, James Chih-Hsin, Prof, Lu, You, Prof, Atagi, Shinji, MD, Ponce, Santiago, MD, Lee, Dae Ho, Prof, Liu, Yunpeng, Prof, Yoh, Kiyotaka, MD, Zhou, Jian-Ying, Prof, Shi, Xiaojin, MD, Webster, Alan, MSc, Jiang, Haiyi, MD, Mok, Tony S K, Prof

“…Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase…”
Get full text

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer by Nishio, Makoto, Nakagawa, Kazuhiko, Mitsudomi, Tetsuya, Yamamoto, Nobuyuki, Tanaka, Tomohiro, Kuriki, Hiroshi, Zeaiter, Ali, Tamura, Tomohide

“…•Alectinib is the preferred first-line treatment option for ALK-positive NSCLC.•Alectinib showed superior efficacy to crizotinib in the J-ALEX phase III…”
Get full text